The purpose of this study is to determine the effectiveness of using Bevacizumab in the
prevention of recurrent malignant ascites.
Ascites is a debilitating and unpleasant complication of several types of cancer. Animal and
laboratory studies have shown that tumor cell production and/or increases in the amount of
Vascular Endothelial Growth Factor (VEGF) is a major cause of the formation of malignant
ascites. Therefore, giving patients with malignant ascites a drug that targets and
neutralizes VEGF should prevent the recurrence of malignant ascites following paracentesis (a
procedure to remove fluid from the abdominal cavity).